vs
EXACT SCIENCES CORP（EXAS）与Fair Isaac（FICO）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Fair Isaac的1.7倍（$878.4M vs $512.0M），Fair Isaac净利率更高（30.9% vs -9.8%，领先40.7%），EXACT SCIENCES CORP同比增速更快（23.1% vs 16.4%），Fair Isaac自由现金流更多（$173.9M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 8.6%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
FICO（原Fair, Isaac and Company）是美国知名数据分析企业，1956年由比尔·费尔与厄尔·艾萨克创立，总部位于蒙大拿州博兹曼市，核心业务为信用评分服务，其推出的FICO信用分是评估消费者信贷风险的重要指标，目前已被美国消费信贷行业广泛采用。
EXAS vs FICO — 直观对比
营收规模更大
EXAS
是对方的1.7倍
$512.0M
营收增速更快
EXAS
高出6.8%
16.4%
净利率更高
FICO
高出40.7%
-9.8%
自由现金流更多
FICO
多$53.4M
$120.4M
两年增速更快
EXAS
近两年复合增速
8.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $512.0M |
| 净利润 | $-86.0M | $158.4M |
| 毛利率 | 70.1% | 83.0% |
| 营业利润率 | -9.4% | 45.7% |
| 净利率 | -9.8% | 30.9% |
| 营收同比 | 23.1% | 16.4% |
| 净利润同比 | 90.1% | 3.8% |
| 每股收益（稀释后） | $-0.45 | $6.61 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFICO
| Q4 25 | $878.4M | $512.0M | ||
| Q3 25 | $850.7M | $515.8M | ||
| Q2 25 | $811.1M | $536.4M | ||
| Q1 25 | $706.8M | $498.7M | ||
| Q4 24 | $713.4M | $440.0M | ||
| Q3 24 | $708.7M | $453.8M | ||
| Q2 24 | $699.3M | $447.8M | ||
| Q1 24 | $637.5M | $433.8M |
净利润EXASFICO
| Q4 25 | $-86.0M | $158.4M | ||
| Q3 25 | $-19.6M | $155.0M | ||
| Q2 25 | $-1.2M | $181.8M | ||
| Q1 25 | $-101.2M | $162.6M | ||
| Q4 24 | $-864.6M | $152.5M | ||
| Q3 24 | $-38.2M | $135.7M | ||
| Q2 24 | $-15.8M | $126.3M | ||
| Q1 24 | $-110.2M | $129.8M |
毛利率EXASFICO
| Q4 25 | 70.1% | 83.0% | ||
| Q3 25 | 68.6% | 82.3% | ||
| Q2 25 | 69.3% | 83.7% | ||
| Q1 25 | 70.8% | 82.4% | ||
| Q4 24 | 69.0% | 80.1% | ||
| Q3 24 | 69.4% | 80.3% | ||
| Q2 24 | 69.8% | 80.3% | ||
| Q1 24 | 70.0% | 80.0% |
营业利润率EXASFICO
| Q4 25 | -9.4% | 45.7% | ||
| Q3 25 | -3.0% | 46.0% | ||
| Q2 25 | -0.3% | 48.9% | ||
| Q1 25 | -13.6% | 49.3% | ||
| Q4 24 | -122.8% | 40.8% | ||
| Q3 24 | -5.6% | 43.4% | ||
| Q2 24 | -3.8% | 42.5% | ||
| Q1 24 | -16.7% | 44.9% |
净利率EXASFICO
| Q4 25 | -9.8% | 30.9% | ||
| Q3 25 | -2.3% | 30.1% | ||
| Q2 25 | -0.1% | 33.9% | ||
| Q1 25 | -14.3% | 32.6% | ||
| Q4 24 | -121.2% | 34.7% | ||
| Q3 24 | -5.4% | 29.9% | ||
| Q2 24 | -2.3% | 28.2% | ||
| Q1 24 | -17.3% | 29.9% |
每股收益（稀释后）EXASFICO
| Q4 25 | $-0.45 | $6.61 | ||
| Q3 25 | $-0.10 | $6.41 | ||
| Q2 25 | $-0.01 | $7.40 | ||
| Q1 25 | $-0.54 | $6.59 | ||
| Q4 24 | $-4.69 | $6.14 | ||
| Q3 24 | $-0.21 | $5.44 | ||
| Q2 24 | $-0.09 | $5.05 | ||
| Q1 24 | $-0.60 | $5.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $162.0M |
| 总债务越低越好 | — | $3.2B |
| 股东权益账面价值 | $2.4B | $-1.8B |
| 总资产 | $5.9B | $1.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASFICO
| Q4 25 | $964.7M | $162.0M | ||
| Q3 25 | $1.0B | $134.1M | ||
| Q2 25 | $858.4M | $189.0M | ||
| Q1 25 | $786.2M | $146.6M | ||
| Q4 24 | $1.0B | $184.3M | ||
| Q3 24 | $1.0B | $150.7M | ||
| Q2 24 | $946.8M | $156.0M | ||
| Q1 24 | $652.1M | $135.7M |
总债务EXASFICO
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.0B |
股东权益EXASFICO
| Q4 25 | $2.4B | $-1.8B | ||
| Q3 25 | $2.5B | $-1.7B | ||
| Q2 25 | $2.5B | $-1.4B | ||
| Q1 25 | $2.4B | $-1.1B | ||
| Q4 24 | $2.4B | $-1.1B | ||
| Q3 24 | $3.2B | $-962.7M | ||
| Q2 24 | $3.2B | $-829.3M | ||
| Q1 24 | $3.1B | $-735.7M |
总资产EXASFICO
| Q4 25 | $5.9B | $1.9B | ||
| Q3 25 | $5.9B | $1.9B | ||
| Q2 25 | $5.8B | $1.9B | ||
| Q1 25 | $5.7B | $1.8B | ||
| Q4 24 | $5.9B | $1.7B | ||
| Q3 24 | $6.7B | $1.7B | ||
| Q2 24 | $6.7B | $1.7B | ||
| Q1 24 | $6.4B | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $174.1M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $173.9M |
| 自由现金流率自由现金流/营收 | 13.7% | 34.0% |
| 资本支出强度资本支出/营收 | 3.6% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $750.6M |
8季度趋势，按日历期对齐
经营现金流EXASFICO
| Q4 25 | $151.7M | $174.1M | ||
| Q3 25 | $219.9M | $223.7M | ||
| Q2 25 | $89.0M | $286.2M | ||
| Q1 25 | $30.8M | $74.9M | ||
| Q4 24 | $47.1M | $194.0M | ||
| Q3 24 | $138.7M | $226.5M | ||
| Q2 24 | $107.1M | $213.3M | ||
| Q1 24 | $-82.3M | $71.0M |
自由现金流EXASFICO
| Q4 25 | $120.4M | $173.9M | ||
| Q3 25 | $190.0M | $219.5M | ||
| Q2 25 | $46.7M | $284.4M | ||
| Q1 25 | $-365.0K | $72.8M | ||
| Q4 24 | $10.7M | $193.2M | ||
| Q3 24 | $112.6M | $224.7M | ||
| Q2 24 | $71.2M | $211.6M | ||
| Q1 24 | $-120.0M | $67.0M |
自由现金流率EXASFICO
| Q4 25 | 13.7% | 34.0% | ||
| Q3 25 | 22.3% | 42.6% | ||
| Q2 25 | 5.8% | 53.0% | ||
| Q1 25 | -0.1% | 14.6% | ||
| Q4 24 | 1.5% | 43.9% | ||
| Q3 24 | 15.9% | 49.5% | ||
| Q2 24 | 10.2% | 47.2% | ||
| Q1 24 | -18.8% | 15.4% |
资本支出强度EXASFICO
| Q4 25 | 3.6% | 0.0% | ||
| Q3 25 | 3.5% | 0.8% | ||
| Q2 25 | 5.2% | 0.3% | ||
| Q1 25 | 4.4% | 0.4% | ||
| Q4 24 | 5.1% | 0.2% | ||
| Q3 24 | 3.7% | 0.4% | ||
| Q2 24 | 5.1% | 0.4% | ||
| Q1 24 | 5.9% | 0.9% |
现金转化率EXASFICO
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.57× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.67× | ||
| Q2 24 | — | 1.69× | ||
| Q1 24 | — | 0.55× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FICO
| Business To Business Scores | $248.6M | 49% |
| Saa S Products | $115.7M | 23% |
| Platform Software | $73.9M | 14% |
| Business To Consumer Scores | $55.9M | 11% |
| Technology Service | $19.2M | 4% |
